Yes-associated protein inhibition ameliorates liver fibrosis and acute and chronic liver failure by decreasing ferroptosis and necroptosis.
Acute-on-chronic liver failure
Ferroptosis
Liver cirrhosis
Necroptosis
Yes-associated protein
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
11
12
2022
revised:
23
03
2023
accepted:
27
03
2023
medline:
8
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
This study aims to determine which cell death modes contribute most in the progression of cirrhosis and acute-on-chronic liver failure (ACLF), and to investigate whether Yes associated protein (YAP) affects the disease process by regulating cell death. 30C57BL/6 male mice were divided into five groups: control, carbon tetrachloride (CCl4)-induced liver fibrosis model, CCl4+verteporfin, CCl4+lipopolysaccharides (LPS) combined with the D-(+)-Galactosamine (LPS/D-GalN)-induced ACLF model, and ACLF + verteporfin. Patients with chronic hepatitis B (CHB), hepatitis B virus (HBV) related liver cirrhosis or ACLF were enrolled. Histology, immunohistochemistry, transmission electron microscopy, Western blot and ELISA were conducted to assess the roles of YAP and cell death in liver cirrhosis and ACLF, and to explore the effect of YAP inhibition on cell deaths. YAP was markedly increased in mice with liver fibrosis and ACLF, along with ferroptosis and necroptosis. Furthermore, YAP inhibition significantly suppressed fibrosis in CCl4-mediated liver fibrosis and ACLF-associated liver injury. Notably, CCl4 induced up-regulation of ACSL4 and RIPK3 and down-regulation of SLC7A11, key factors in ferroptosis and necroptosis. This was significantly abrogated by verteporfin treatment. Similar changes in ferroptosis and necroptosis were found in ACLF and ACLF + verteporfin groups. Consistent with the above findings in mice, we found that plasma YAP levels were gradually increased with the development of HBV-related liver fibrosis and ACLF. Ferroptosis and necroptosis are involved in the development of liver cirrhosis and ACLF. Inhibition of YAP improved liver fibrosis and liver damage in ACLF through a reduction in ferroptosis and necroptosis. Our findings may help better understanding the role of YAP in liver fibrosis and ACLF.
Sections du résumé
Background/aims
UNASSIGNED
This study aims to determine which cell death modes contribute most in the progression of cirrhosis and acute-on-chronic liver failure (ACLF), and to investigate whether Yes associated protein (YAP) affects the disease process by regulating cell death.
Materials and methods
UNASSIGNED
30C57BL/6 male mice were divided into five groups: control, carbon tetrachloride (CCl4)-induced liver fibrosis model, CCl4+verteporfin, CCl4+lipopolysaccharides (LPS) combined with the D-(+)-Galactosamine (LPS/D-GalN)-induced ACLF model, and ACLF + verteporfin. Patients with chronic hepatitis B (CHB), hepatitis B virus (HBV) related liver cirrhosis or ACLF were enrolled. Histology, immunohistochemistry, transmission electron microscopy, Western blot and ELISA were conducted to assess the roles of YAP and cell death in liver cirrhosis and ACLF, and to explore the effect of YAP inhibition on cell deaths.
Results
UNASSIGNED
YAP was markedly increased in mice with liver fibrosis and ACLF, along with ferroptosis and necroptosis. Furthermore, YAP inhibition significantly suppressed fibrosis in CCl4-mediated liver fibrosis and ACLF-associated liver injury. Notably, CCl4 induced up-regulation of ACSL4 and RIPK3 and down-regulation of SLC7A11, key factors in ferroptosis and necroptosis. This was significantly abrogated by verteporfin treatment. Similar changes in ferroptosis and necroptosis were found in ACLF and ACLF + verteporfin groups. Consistent with the above findings in mice, we found that plasma YAP levels were gradually increased with the development of HBV-related liver fibrosis and ACLF.
Conclusion
UNASSIGNED
Ferroptosis and necroptosis are involved in the development of liver cirrhosis and ACLF. Inhibition of YAP improved liver fibrosis and liver damage in ACLF through a reduction in ferroptosis and necroptosis. Our findings may help better understanding the role of YAP in liver fibrosis and ACLF.
Identifiants
pubmed: 37151632
doi: 10.1016/j.heliyon.2023.e15075
pii: S2405-8440(23)02282-X
pmc: PMC10161368
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e15075Informations de copyright
© 2023 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Hepatology. 2015 Apr;61(4):1306-20
pubmed: 25475192
Hepatology. 2013 May;57(5):1773-83
pubmed: 23319235
Histol Histopathol. 2021 Sep;36(9):967-979
pubmed: 34490599
Trends Cell Biol. 2022 Sep;32(9):729-732
pubmed: 35701310
Gastroenterology. 2015 Mar;148(3):603-615.e14
pubmed: 25479139
Clin Liver Dis. 2021 May;25(2):419-430
pubmed: 33838858
Cell. 2012 Jan 20;148(1-2):228-43
pubmed: 22265414
Nat Rev Gastroenterol Hepatol. 2021 Mar;18(3):151-166
pubmed: 33128017
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
Mol Immunol. 2019 Mar;107:29-40
pubmed: 30639476
Cell Death Differ. 2020 Jul;27(7):2234-2247
pubmed: 31988496
Cell Death Dis. 2021 Dec 17;13(1):5
pubmed: 34921136
Hepatology. 2014 Mar;59(3):898-910
pubmed: 23813842
Gut. 2017 Mar;66(3):541-553
pubmed: 28053053
Autophagy. 2020 Aug;16(8):1482-1505
pubmed: 31679460
Nat Chem Biol. 2017 Jan;13(1):91-98
pubmed: 27842070
J Immunol Res. 2018 Nov 25;2018:1509851
pubmed: 30596105
Evid Based Complement Alternat Med. 2012;2012:241583
pubmed: 22649471
J Clin Invest. 1998 Aug 1;102(3):538-49
pubmed: 9691091
Free Radic Biol Med. 2020 Nov 20;160:845-859
pubmed: 32947011
Arch Pharm Res. 2020 Oct;43(10):985-996
pubmed: 33079307
BMC Gastroenterol. 2020 Oct 12;20(1):332
pubmed: 33045993
Blood. 2020 Aug 6;136(6):726-739
pubmed: 32374849
Cell Death Dis. 2021 Jan 18;12(1):93
pubmed: 33462187
J Hepatol. 2015 Dec;63(6):1491-501
pubmed: 26226451
J Hepatol. 2015 Jul;63(1):50-9
pubmed: 25646889
Free Radic Biol Med. 2019 Mar;133:130-143
pubmed: 30268886
Autophagy. 2018;14(12):2083-2103
pubmed: 30081711
J Mol Biol. 2015 Oct 23;427(21):3407-15
pubmed: 25937570
Nature. 2015 Jan 15;517(7534):311-20
pubmed: 25592536
Mol Cell Oncol. 2019 Dec 10;7(1):1699375
pubmed: 31993503
Hepatology. 2016 Jul;64(1):232-44
pubmed: 26970079
Liver Int. 2017 Feb;37(2):232-241
pubmed: 27473364
Sci Signal. 2013 Sep 03;6(291):ra77
pubmed: 24003254
Hepatology. 2015 Dec;62(6):1847-57
pubmed: 26077809
Cell Rep. 2019 Sep 3;28(10):2501-2508.e4
pubmed: 31484063
Int J Mol Sci. 2020 Dec 18;21(24):
pubmed: 33353156
Oxid Med Cell Longev. 2022 Apr 16;2022:4505513
pubmed: 35480867
Cell Biol Toxicol. 2020 Apr;36(2):145-164
pubmed: 31820165
Front Med (Lausanne). 2015 Sep 03;2:59
pubmed: 26389119
Evid Based Complement Alternat Med. 2012;2012:137083
pubmed: 22988470
J Biochem. 2012 Jul;152(1):5-15
pubmed: 22661765
Hepatol Res. 2012 Feb;42(2):171-80
pubmed: 22103276
J Exp Med. 1998 May 4;187(9):1477-85
pubmed: 9565639
Nature. 2019 Aug;572(7769):402-406
pubmed: 31341276
Lancet. 2015 Oct 17;386(10003):1576-87
pubmed: 26423181
Cell. 2014 Aug 14;158(4):833-848
pubmed: 25126788
Cell Rep. 2013 Nov 27;5(4):1060-9
pubmed: 24268772
Biomark Med. 2021 Oct;15(15):1411-1422
pubmed: 34533050
Immunity. 2013 Feb 21;38(2):209-23
pubmed: 23438821
EMBO Mol Med. 2021 Dec 7;13(12):e14351
pubmed: 34664408
Cell Res. 2020 Dec;30(12):1061-1062
pubmed: 33149249